Navigation Links
Boehringer Ingelheim Unveils Diabetes Pipeline
Date:6/6/2009

RIDGEFIELD, Conn., June 6 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced its pipeline of oral antidiabetic compounds, establishing itself in the type 2 diabetes therapeutic area. The Company is investigating compounds in Phase II and Phase III clinical development worldwide. New Phase II data results for linagliptin (BI 1356), a dipeptidyl peptidase 4 (DPP-4) inhibitor and the Company's lead diabetes compound, were presented today at the 69th Annual American Diabetes Association (ADA) Scientific Sessions in New Orleans.

"Type 2 diabetes is a growing public health concern," said J. Martin Carroll, Boehringer Ingelheim USA Corporation president and CEO. "Our Company will draw from its knowledge and experience to help us deliver on the much needed treatment options for patients who are living with the disease. Boehringer Ingelheim is inspired to make a difference in diabetes care."

Results from the Phase II study presented at ADA show that 1, 5 and 10 mg doses of linagliptin achieved clinically relevant and statistically significant reductions in HbA1c, a measure of blood sugar, when given as add-on therapy to type 2 diabetes patients inadequately controlled on metformin (placebo-corrected changes from baseline; -0.40 percent for the 1 mg dose, -0.73 percent for the 5 mg dose, and -0.67 percent for the 10 mg dose).(1) The most frequently reported adverse events in patients treated with all doses of linagliptin compared to placebo were nasopharyngitis, (7.1 vs. 9.9 percent) diarrhea (2.5 vs. 4.2 percent) and nausea (3.5 vs. 4.2 percent). No cases of hypoglycemia were reported in patients receiving linagliptin.(1)

"Many patients don't achieve adequate blood sugar control with commonly used diabetes medications like metformin. The significant reduction in HbA1c levels seen in this trial is encouraging as it indicates linagliptin may have a potential role in t
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
2. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
3. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
4. Ferring Pharmaceuticals Unveils Six-Month Efficacy Data for EUFLEXXA(R) for the Treatment of Osteoarthritis Knee Pain
5. OmegaGenesis Unveils Novel Nanotechnology Platform With Broad Biomedical Applications
6. Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention
7. NeoVista Unveils 18-month Data on Novel Wet AMD Therapy at Retina Society Meeting
8. Oregon Tourism Commission Unveils New Online Customer Service Training Program
9. AFRESA(R) Phase 3 Pulmonary Function Safety Data in Patients with Diabetes Presented at ADA
10. Large, Long-Term Study Shows Avandia Has No Increased Overall Cardiovascular Risk Compared to Other Commonly Used Diabetes Medicines
11. Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Associations 69th Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014  Zafgen, Inc., a leading biopharmaceutical ... severely obese patients, today announced initial results from ... inhibitor of methionine aminopeptidase 2 (MetAP2), in patients ... genetic obesity.  These results showed improvements in body ...
(Date:1/14/2014)... InformEx, North America,s leading business partnering ... the 30 th edition of its annual conference at ... January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... and specialty chemical companies will take part in the conference, ...
(Date:1/14/2014)... Emergency Critical Care, a LifeCentre partner practice, located at 165 Fort ... first in Loudoun County to receive a ... M. Barnes , Medical Director, is a well-seasoned veterinarian of more ... , are avid scuba divers. "As altitude skiers and hikers, we ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2
... 15, 2011 Amgen (NASDAQ: AMGN ... District Court in Pennsylvania has entered final judgment ... Ltd. and Teva Pharmaceuticals USA prohibiting them from ... colony-stimulating factor) and methods for its use. Today,s ...
... key component of health care reform involves the improvement ... particularly for patients admitted to a hospital. To help ... Center for Health Quality and Innovation, which provides financial ... system. The center has now awarded nine ...
Cached Medicine Technology:Amgen Resolves G-CSF Patent Litigation With Teva 2UCLA Receives Six UC Health Quality Grants to Improve Hospital Care 2UCLA Receives Six UC Health Quality Grants to Improve Hospital Care 3UCLA Receives Six UC Health Quality Grants to Improve Hospital Care 4UCLA Receives Six UC Health Quality Grants to Improve Hospital Care 5
(Date:4/23/2014)... program could help doctors predict which patients might suffer ... , The program, which assesses brain scans using pattern ... and passport control, has been developed by researchers at ... by the Wellcome Trust, which used the software are ... , Stroke affects over 15 million people each year ...
(Date:4/23/2014)... showing the potential health benefits of probiotics, antioxidants and ... supplements. And the chemical industry is getting in on ... could deter growth, so the industry is responding with ... the cover story in Chemical & Engineering News ... Chemical Society. , Melody M. Bomgardner, a senior editor ...
(Date:4/23/2014)... Five for-profit and non-profit organizations in Washington will ... of Concept grants to accelerate maturation of promising ... Life Sciences Discovery Fund (LSDF) announced today. Also ... to the Washington Biotechnology & Biomedical Association (WBBA) ... the next generation of entrepreneurs and help early-stage ...
(Date:4/23/2014)... Midlife Occupational and Leisure Time Physical Activity on Mobility ... in midlife increases the risk of mobility limitation in ... This is found in a study which followed up ... was conducted at the Gerontology Research Center in Finland ... physical labor is often repetitive, wears the body and ...
(Date:4/23/2014)... endogenous neural precursor cells cannot alone compensate for ... perspective of neural plasticity, Dr. Yun Xiang and ... the effects of functional electrical stimulation treatment on ... basic fibroblast growth factor and epidermal growth factor ... The researchers found that functional electrical stimulation can ...
Breaking Medicine News(10 mins):Health News:Airport security-style technology could help doctors decide on stroke treatment 2Health News:Airport security-style technology could help doctors decide on stroke treatment 3Health News:LSDF announces commercialization grants and Entrepreneur Mentoring Program 2Health News:Midlife occupational and leisure-time physical activity limits mobility in old age 2
... , WASHINGTON, Sept. 18 In the ... is considered a "pre-existing condition" by many health insurers, today ... police officers, war correspondents, expectant fathers, pregnant women and patients ... denied health insurance policies. , , The ...
... various routes , FRIDAY, Sept. 18 (HealthDay News) -- ... the U.S. Food and Drug Administration can be safely ... new recommendations from the American Academy of Allergy, Asthma ... responses are weakened by medical treatments (such as for ...
... , SAN FRANCISCO, Sept. 18 Quantros(TM), ... healthcare industry, today announced a partnership with HealthWatch, Inc. - a ... Care, a national, not for profit quality improvement organization - to ... , , Quantros Patient Safety Center (QPSC(TM)), the ...
... Sept. 18 happier.com is a ... designed to help people not just be happier but "do happier. ... for users to make an immediate positive impact on ... by taking 4 validated tests with instant feedback on ...
... , Active sculptor and wood carver makes quick return ... six years of dialysis finally began to take a heavy toll on 84-year-old ... his art, and he was unable to travel, which is a major source ... patriarch to an expansive family. He,s the father of four, grandfather of five ...
... SHANGHAI, Sept. 18 /PRNewswire-Asia/ -- Avery Dennison Specialty Tape,Division, ... sector,introduced two new ultra-thin adhesives and a hydrocolloid and ... (Photo: http://www.prnasia.com/sa/2009/09/18/20090918839634.html ) , ... entire spectrum of wound care and for the most,demanding ...
Cached Medicine News:Health News:Pre-Existing Health 'Conditions' - Cops, Firefighters, Expectant Dads, and Those Suffering From Allergies, Acne and Toenail Fungus Are Uninsurable According to Internal Documents 2Health News:Swine Flu Shots Safe for People With Weak Immune Systems: Experts 2Health News:Swine Flu Shots Safe for People With Weak Immune Systems: Experts 3Health News:Quantros and HealthWatch Announce PSO Partnership 2Health News:Quantros and HealthWatch Announce PSO Partnership 3Health News:https://happier.com/form.htmhappier.com Launches a Personal Trainer for Your Happiness 2Health News:Kidney Transplant at 84, Chicago Artist Proves New Start Possible at Any Age 2Health News:Kidney Transplant at 84, Chicago Artist Proves New Start Possible at Any Age 3Health News:Kidney Transplant at 84, Chicago Artist Proves New Start Possible at Any Age 4Health News:Avery Dennison Introduces Advanced New Medical Dressing Technology at MEDTEC China 2009 2Health News:Avery Dennison Introduces Advanced New Medical Dressing Technology at MEDTEC China 2009 3
Manufacturer of the WellPro since 1992, ProGroup previously distributed the instrument through Denley and Labsystems. A direct replacement for the ProPette the WellPro performs serial dilutions in an...
... compatible with hood installations. ... system for 384-well plates, ... prepares large quantities of ... Wellpro also performs plate ...
... The Aquarius 384 is a ... Aquarius 384-well head is a unique ... washing using the included wash system. ... 250 microplate stacker system. Will ...
... new Nanopipetting System Genesis NPS based on ... allows you to miniaturize your assays for ... picking and direct dilutions., Furthermore it ... applications including gene expression analysis, gene mapping, ...
Medicine Products: